This study found that the combination of AZ628 and BP-1-102 showed a strongly synergistic interaction in KRAS-mutant lung cancer cells compared with wild-type cancer cells, and KRAS-mutant lung cancer cells were more sensitive to this combination than AZ628 or BP-1-102 single. Here, KRAS is linked to lung carcinoma.